Skip to main content

Rheumatoid Arthritis

      #Poorer responses to #Rx in
      #Females vs #males

      Sex hormone and pathway differences
      explained
      👇
      Biological differe
      4 months 2 weeks ago
      #Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA.
      RA patients vaccinated with PCV13
      4 months 2 weeks ago
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropos
      4 months 2 weeks ago
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA
      4 months 2 weeks ago
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA a
      4 months 2 weeks ago
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe
      The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…
      Day 3 Recap: ACR 2024
      Is Pregnancy Truly the Solution for RA?

      Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has
      4 months 2 weeks ago
      Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu
      ×